The purpose of this study is to evaluate whether 18F-FDG PET/CT-based prognostic model of diffuse large B-cell lymphoma can predict disease progression

In this study investigators develop a prognostic model based on 18F-FDG PET/CT and test its ability for prognostic value in patients with DLBCL. PET/CT scans evaluation using the liver SUVmax as reference. Positive lesions in PET were indicated as SUVmax of residues higher than the threshold (1.6 fold of liver SUVmax) or new 18F-FDG avid lesions. 18F-FDG PET/CT-based prognostic model includes PET/CT image, dominant clinical and pathological prognostic factors to predicting disease progression during chemotherapy or survival in DLBCL.

Inclusion Criteria:

1. newly diagnosed DLBCL;
2. treated using an anthracycline-containing regimen with or without rituximab;
3. minimal follow-up at 6 months after the completion of first-line treatment;
4. complete medical history and clinicopathological data

Exclusion Criteria:

1. secondary malignant disease;
2. serious infection or inflammation (e.g., HIV);
3. primary central nervous system lymphoma;
4. hepatic or renal dysfunction.